EC Number |
Natural Substrates |
---|
3.5.4.1 | 5-fluorocytosine + H2O |
activation of the prodrug 5-fluorocytosine to the anticander drug 5-fluorouracil |
3.5.4.1 | 5-fluorocytosine + H2O |
activation of the prodrug by the recombinant fusion enzyme, overview |
3.5.4.1 | 5-fluorocytosine + H2O |
inside a cell, cytosine and 5-fluorocytosine compete for the active site of the enzyme |
3.5.4.1 | 5-fluorocytosine + H2O |
recombinant enzyme encoded in an adenoviral vector expressed in murine cancers or human cancer cell lines for prodrug cancer gene therapy, Ad/5HREp-BCD-mediated cytotoxicity under hypoxic conditions, overview |
3.5.4.1 | 5-fluorocytosine + H2O |
recombinant enzyme in gene therapy in human glioblastoma cell lines Y87-1 and Y87-2 |
3.5.4.1 | 5-fluorocytosine + H2O |
recombinant enzyme in transfected cells, cytotoxic effects of the enzyme expressed form the AdLPCD vector, overview |
3.5.4.1 | 5-fluorocytosine + H2O |
recombinant enzyme, combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice in gene-directed enzyme prodrug therapy, overview |
3.5.4.1 | 5-fluorocytosine + H2O |
recombinant fusion enzyme, cytotoxicity could be enhanced by concurrently treating TKglyCD-expressing cells with prodrugs ganclocivir and 5-fluorocytosine, overview |
3.5.4.1 | 5-fluorocytosine + H2O |
recombinant protein of cytosine deaminase used as antigen for biopanning approach, antibody-directed enzyme-prodrug therapy (GDEPT/ADEPT), binding of specific single chain fragment variable (scFv) with cytosine deaminase does not interfere with enzyme activity |
3.5.4.1 | 5-fluorocytosine + H2O |
used as negative selection marker system, increased 5-fluorocytosine sensitivity in Streptomyces lividans |